An interventional study of Plase-Locked Acoustic Stimulation during slow-wave sleep and Phase-locked acoustic stimulation-Sham condition in Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI) Amnestic and Cognitively Unimpaired, sponsored by Institut de Recerca Biomèdica de Lleida-Fundació Dr. Pifarré (IRBLleida). Not yet recruiting at 1 site in Spain. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Institut de Recerca Biomèdica de Lleida-Fundació Dr. Pifarré (IRBLleida) · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 279 studies in Alzheimer Disease with a site in Spain — 54 open to participants now, 80 under way, 24 of them phase 3. Alzheimer Disease · Spain.
Among the 279 studies in Alzheimer Disease with a site in Spain, this one is the 168th largest by planned enrollment of the 240 interventional ones that give a count, is one of 19 that started in 2026, is one of 66 with no phase, reaches primary completion later than 42 of the 79 other live ones, and was the 269th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →54 of the 279 studies in Alzheimer Disease with a site in Spain are open now. Recruiting first, the newest first:
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation · Sites in Spain
Ages 55–85
Sanofi · Sites in Spain, United States, Australia and 4 more countries
Ages 55–85
Eidos Therapeutics, a BridgeBio company · Sites in Spain, United States, Singapore
Ages 18–80
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Sites in Spain, Australia, Austria and 14 more countries
Ages 18+
Exciva GmbH · Sites in Spain, United States, Canada and 6 more countries
Ages 55–90
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
279 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 81 · Phase 3 94 · Phase 4 4
First in 2002; this study’s year is marked. 19 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 114 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 258 across the 240 interventional studies, 400 across the 39 observational. Of the 187 that completed or were terminated, 91 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
178 of 279 have an industry lead sponsor. The 10 most frequent:
Institut de Recerca Biomèdica de Lleida-Fundació Dr. Pifarré (IRBLleida) is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Institut de Recerca Biomèdica de Lleida-Fundació Dr. Pifarré (IRBLleida) has 1 study filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
20 of the studies in Alzheimer Disease with a site in Spain that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
| NCT07682155Germans Trias i Pujol HospitalStudy of the Brain's Natural Cleaning System in Potential Organ Donors. | 2026-11-30 |
| NCT07639645University of ValenciaIntervention to Reduce Unwanted Loneliness in Family Caregivers of People With Alzheimer | 2026-12 |
Add all 20 to your calendar (.ics) → With an account.
Among the 279 studies in Alzheimer Disease with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to determine whether acoustic stimulation during sleep can enhance slow-wave sleep (SWS), improve cognitive function, and reduce AD-related pathology in individuals with mild cognitive impairment (MCI), compared with cognitively healthy participants.
The main questions it aims to answer are:
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Receiving phase-locked acoustic stimulation as an intervention
Device: Plase-Locked Acoustic Stimulation during slow-wave sleep
Will have the same montage as real-PLAS, but no stimulation will be produced
Device: Phase-locked acoustic stimulation-Sham condition
Participants will wear a mobile, wearable EEG device during sleep. Sleep will be recorded using EEG, and an algorithm will detect slow oscillations (SOs; \>1 Hz). In the real-PLAS arm, acoustic stimulation will be applied in phase with the up-state of these slow oscillations. Specifically, the algorithm will detect each SO and trigger brief pink-noise bursts synchronized with the up-state phase, ensuring phase-locked acoustic stimulation (PLAS) is delivered precisely to enhance slow-wave activity.
Also known as: Closed-loop acoustic stimulation, Closed-loop auditive stimulation
Participants will have the same setup as in the real-PLAS arm, wearing a mobile, wearable EEG device during sleep. Sleep will be recorded using EEG, and an algorithm will detect slow oscillations (SOs; \>1 Hz). No acoustic stimulation will be applied in the sham-PLAS arm.
Impact on SWS: SO and sleep spindle density
Two defining features of slow-wave sleep (SWS) are slow oscillations (SO) and sleep spindles. Accordingly, the impact of multi-night PLAS on SWS in the study population will be evaluated by measuring the density of both features (expressed as counts per 30 seconds). Post-intervention measurements, including follow-up assessments, will be compared with the baseline night, during which no stimulation is applied, and with the sham group.
Time frame: 14 nights
Impact on SWS: SO and sleep spindle duration
Two defining features of slow-wave sleep (SWS) are slow oscillations (SO) and sleep spindles. Accordingly, the impact of multi-night PLAS on SWS in the study population will be evaluated by measuring the duration of both features (expressed in seconds). Post-intervention measurements, including follow-up assessments, will be compared with the baseline night, during which no stimulation is applied, and with the sham group.
Time frame: 14 nights
Impact on SWS: SO and sleep spindle peak-to-peak amplitude
Two defining features of slow-wave sleep (SWS) are slow oscillations (SO) and sleep spindles. Accordingly, the impact of multi-night PLAS on SWS in the study population will be evaluated by measuring the peak-to-peak amplitude of both features (expressed in µV).Post-intervention measurements, including follow-up assessments, will be compared with the baseline night, during which no stimulation is applied, and with the sham group.
Time frame: 14 nights
Impact on SWS: SO and sleep spindle peak power frequency
Two defining features of slow-wave sleep (SWS) are slow oscillations (SO) and sleep spindles. Accordingly, the impact of multi-night PLAS on SWS in the study population will be evaluated by measuring the peak power frequency of each feature (expressed in Hz). Post-intervention measurements, including follow-up assessments, will be compared with the baseline night, during which no stimulation is applied, and with the sham group.
Time frame: 14 nights
Impact on SWS: SO and sleep spindle power
Two defining features of slow-wave sleep (SWS) are slow oscillations (SO) and sleep spindles. Accordingly, the impact of multi-night PLAS on SWS in the study population will be evaluated by measuring the power of both features (expressed in µV2). Post-intervention measurements, including follow-up assessments, will be compared with the baseline night, during which no stimulation is applied, and with the sham group.
Time frame: 14 nights
Impact on declarative memory consolidation: correct performance in the Verbal Paired Associates test
The impact of multi-night PLAS on declarative memory performance in the study population will be assessed using the Verbal Paired Associates (VPA) test. Performance will be quantified as the number of correctly recalled word pairs. Post-intervention measurements, including follow-up assessments, will be compared with the first recall, conducted in the morning after the baseline night, and with the sham group.
Time frame: Up to 3 months after intervention
Impact on procedural memory consolidation: correct performance in the Motor Sequence Typing task
The impact of multi-night PLAS on procedural memory performance in the study population will be assessed using the Motor Sequence Typing task (MST). Performance will be quantified as the number of correctly executed sequences (i.e., keypresses) per trial. Post-intervention measurements, including follow-up assessments, will be compared with the first recall, conducted in the morning after the baseline night, and with the sham group.
Time frame: Up to 3 months after intervention
Impact on procedural memory consolidation: incorrect performance in the Motor Sequence Typing task
The impact of multi-night PLAS on procedural memory performance in the study population will be assessed using the Motor Sequence Typing task (MST). Performance will be quantified as the number of incorrectly executed sequences (i.e., keypresses) per trial. Post-intervention measurements, including follow-up assessments, will be compared with the first recall, conducted in the morning after the baseline night, and with the sham group.
Time frame: Up to 3 months after intervention
Impact on procedural memory consolidation: total attempt performance in the Motor Sequence Typing task
The impact of multi-night PLAS on procedural memory performance in the study population will be assessed using the Motor Sequence Typing Task (MST). Performance will be quantified as the total number of executed sequences (i.e., keypresses) per trial. Post-intervention measurements, including follow-up assessments, will be compared with the first recall, conducted in the morning after the baseline night, and with the sham group.
Time frame: Up to 3 months after intervention
Impact on p-tau217
Post-intervention plasma levels of p-tau217(pg/mL), including follow-up assessments, will be measured in the study population and compared with baseline values as well as with the sham group.
Time frame: Up to 3 months after intervention
Effect on GFAP and NfL
Post-intervention plasma levels of Glial fibrillary acidic protein (GFAP, pg/mL) and neurofilament light (NfL, pg/mL), including follow-up assessments, will be measured in the study population and compared with baseline values as well as with the sham group.
Time frame: Up to 3 months after intervention
Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.
Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 12 months is below that.
Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: start Apr 2026 → Dec 2026 and primary completion Sep 2027 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut de Recerca Biomèdica de Lleida-Fundació Dr. Pifarré (IRBLleida)